Follows antibody changes in people with severe hemophilia A taking emicizumab
Follows antibody changes in people with severe hemophilia A on emicizumab treatment.
Plain-language title generated from the registry record
Registry title: Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab
Key facts
- Where
- Frankfurt am Main, GermanySee the site
Where in Germany
- University Hospital Frankfurt, Goethe UniversityFrankfurt am Main, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Christoph Königs
- Trial code
- NCT05802836
- Record updated
- 10 July 2023
- Original description
The goal of this observational study is to learn about the changes of antibodies and inhibitors against the coagulation factor VIII in patients with severe hemophilia A receiving emicizumab therapy. No additional visits or procedures are planned. Patients in this study will continue to receive their routine care and analysis will be done from left over samples from routine visits.Read full original descriptionShow less
Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab
The goal of this observational study is to learn about the changes of antibodies and inhibitors against the coagulation factor VIII in patients with severe hemophilia A receiving emicizumab therapy. No additional visits or procedures are planned. Patients in this study will continue to receive their routine care and analysis will be done from left over samples from routine visits.
Inclusion: Severe congenital hemophilia A (CHA); Treatment with emicizumab irrespective of any other treatment; Informed consent.
Exclusion: No therapy with emicizumab; Immunosuppressive therapy; HIV-infection with CD4 (cluster of differentiation 4) cells <200/µl.